

REMARKS

Claims 1-29 are pending in this application. Applicants acknowledge the Examiner's restriction requirement under 35 U.S.C. § 121 of the pending claims. Applicants elect to prosecute claims 1-19, and 21-29 (Group I), relating to isolated proteins having a receptor serine/threonine kinase domains, etc. Please cancel the remaining claim, i.e., claim 20, drawn to an antibody (Group II).


Applicants make this election with traverse since claim 20 is dependent from claim 1 and is then linked to the invention embraced by independent claim 1.

In the event the restriction requirement is maintained, then Applicants expressly reserve their rights to pursue the subject matter of canceled claim 20 in a subsequent divisional application.

There is no need to change the inventorship.

Respectfully submitted,

FELFE & LYNCH

By 
Vineet Kohli
Reg. No. 37,003

805 Third Avenue
New York, New York 10022
(212) 688-9200